Title: Bilirubin suppresses Th17 immunity in colitis by upregulating CD39.

Authors: Longhi, Maria Serena; Vuerich, Marta; Kalbasi, Alireza; Kenison, Jessica E; Yeste, Ada; Csizmadia, Eva; Vaughn, Byron; Feldbrugge, Linda; Mitsuhashi, Shuji; Wegiel, Barbara; Otterbein, Leo; Moss, Alan; Quintana, Francisco J; Robson, Simon C

Published In JCI Insight, (2017 May 04)

Abstract: Unconjugated bilirubin (UCB), a product of heme oxidation, has known immunosuppressant properties but the molecular mechanisms, other than antioxidant effects, remain largely unexplored. We note that UCB modulates T helper type 17 (Th17) immune responses, in a manner dependent upon heightened expression of CD39 ectonucleotidase. UCB has protective effects in experimental colitis, where it enhances recovery after injury and preferentially boosts IL-10 production by colonic intraepithelial CD4+ cells. In vitro, UCB confers immunoregulatory properties on human control Th17 cells, as reflected by increased levels of FOXP3 and CD39 with heightened cellular suppressor ability. Upregulation of CD39 by Th17 cells is dependent upon ligation of the aryl hydrocarbon receptor (AHR) by UCB. Genetic deletion of CD39, as in Entpd1-/- mice, or dysfunction of AHR, as in Ahrd mice, abrogates these UCB salutary effects in experimental colitis. However, in inflammatory bowel disease (IBD) samples, UCB fails to confer substantive immunosuppressive properties upon Th17 cells, because of decreased AHR levels under the conditions tested in vitro. Immunosuppressive effects of UCB are mediated by AHR resulting in CD39 upregulation by Th17. Boosting downstream effects of AHR via UCB or enhancing CD39-mediated ectoenzymatic activity might provide therapeutic options to address development of Th17 dysfunction in IBD.

PubMed ID: 28469075

MeSH Terms: No MeSH terms associated with this publication